Similar to PRRT for NET, recent reports have shown substantial benefit of PSMA-based RLT for end-stage PC patients with extensive tumor load, with a parallel decrease of tumor marker (prostate-specific antigen, PSA) levels [2]. This evidence concerns the gene FOLH1 and pachyonychia congenita.